

ICD-10 Procedure Coding System (ICD-10-PCS) 2024 Tables Addenda

ICD-10-PCS Tables that have changed this year are shown in table format in the pages below. Click on a bookmark to go to a specific table.

Each table shown in the addenda replaces the table from the previous year.

00H

No change	Section 0 Medical and Surgical			
	Body System 0 Central Nervous System and Cranial Nerves			
	Operation H Insertion: Putting in a nonbiological appliance that monitors, assists, performs, or prevents a physiological function but does not physically take the place of a body part			
Heading	Body Part	Approach	Device	Qualifier
FY2024	0 Brain	0 Open	1 Radioactive Element 2 Monitoring Device 3 Infusion Device 4 Radioactive Element, Cesium-131 Collagen Implant 5 Radioactive Element, Palladium-103 Collagen Implant M Neurostimulator Lead Y Other Device	Z No Qualifier
No change	0 Brain	3 Percutaneous 4 Percutaneous Endoscopic	1 Radioactive Element 2 Monitoring Device 3 Infusion Device M Neurostimulator Lead Y Other Device	Z No Qualifier
No change	6 Cerebral Ventricle E Cranial Nerve U Spinal Canal V Spinal Cord	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	1 Radioactive Element 2 Monitoring Device 3 Infusion Device M Neurostimulator Lead Y Other Device	Z No Qualifier

025

No change	<i>Section</i>	0	Medical and Surgical	
	<i>Body System</i>	2	Heart and Great Vessels	
	<i>Operation</i>	5	Destruction: Physical eradication of all or a portion of a body part by the direct use of energy, force, or a destructive agent	
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device</i>	<i>Qualifier</i>
FY2024	4 Coronary Vein 5 Atrial Septum 6 Atrium, Right 9 Chordae Tendineae D Papillary Muscle F Aortic Valve G Mitral Valve H Pulmonary Valve J Tricuspid Valve K Ventricle, Right L Ventricle, Left M Ventricular Septum N Pericardium P Pulmonary Trunk Q Pulmonary Artery, Right R Pulmonary Artery, Left S Pulmonary Vein, Right T Pulmonary Vein, Left V Superior Vena Cava W Thoracic Aorta, Descending X Thoracic Aorta, Ascending/Arch	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	Z No Device	Z No Qualifier
No change	7 Atrium, Left	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	Z No Device	K Left Atrial Appendage Z No Qualifier
FY2024	8 Conduction Mechanism	0 Open 4 Percutaneous Endoscopic	Z No Device	Z No Qualifier
FY2024	8 Conduction Mechanism	3 Percutaneous	Z No Device	F Irreversible Electroporation Z No Qualifier

07T

FY2024	Section 0 Medical and Surgical			
	Body System 7 Lymphatic and Hemic Systems			
	Operation T Resection: Cutting out or off, without replacement, all of a body part			
Heading	Body Part	Approach	Device	Qualifier
FY2024	0 Lymphatic, Head 1 Lymphatic, Right Neck 2 Lymphatic, Left Neck 3 Lymphatic, Right Upper Extremity 4 Lymphatic, Left Upper Extremity 5 Lymphatic, Right Axillary 6 Lymphatic, Left Axillary 7 Lymphatic, Thorax 8 Lymphatic, Internal Mammary, Right 9 Lymphatic, Internal Mammary, Left B Lymphatic, Mesenteric C Lymphatic, Pelvis D Lymphatic, Aortic F Lymphatic, Right Lower Extremity G Lymphatic, Left Lower Extremity H Lymphatic, Right Inguinal J Lymphatic, Left Inguinal K Thoracic Duct L Cisterna Chyli M Thymus	0 Open 4 Percutaneous Endoscopic	Z No Device	Z No Qualifier
FY2024	P Spleen	0 Open	Z No Device	Z No Qualifier
FY2024	P Spleen	4 Percutaneous Endoscopic	Z No Device	G Hand-Assisted Z No Qualifier

097

No change	<i>Section</i> 0 Medical and Surgical			
	<i>Body System</i> 9 Ear, Nose, Sinus			
	<i>Operation</i> 7 Dilation: Expanding an orifice or the lumen of a tubular body part			
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device</i>	<i>Qualifier</i>
No change	F Eustachian Tube, Right	0 Open	D Intraluminal Device	Z No Qualifier
	G Eustachian Tube, Left	7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	Z No Device	
No change	F Eustachian Tube, Right	3 Percutaneous	Z No Device	Z No Qualifier
	G Eustachian Tube, Left	4 Percutaneous Endoscopic		
FY2024	N Nasopharynx	0 Open 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	Z No Device	Z No Qualifier

ODB

No change	Section 0 Medical and Surgical			
	Body System D Gastrointestinal System			
	Operation B Excision: Cutting out or off, without replacement, a portion of a body part			
Heading	Body Part	Approach	Device	Qualifier
FY2024	1 Esophagus, Upper 2 Esophagus, Middle 3 Esophagus, Lower 4 Esophagogastric Junction 5 Esophagus 7 Stomach, Pylorus 8 Small Intestine 9 Duodenum A Jejunum B Ileum C Ileocecal Valve E Large Intestine H Cecum K Ascending Colon P Rectum	0 Open 3 Percutaneous 4 Percutaneous Endoscopic 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	Z No Device	X Diagnostic Z No Qualifier
No change	6 Stomach	0 Open 3 Percutaneous 4 Percutaneous Endoscopic 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	Z No Device	3 Vertical X Diagnostic Z No Qualifier
FY2024	F Large Intestine, Right J Appendix	0 Open 3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	Z No Device	X Diagnostic Z No Qualifier
FY2024	F Large Intestine, Right J Appendix	4 Percutaneous Endoscopic	Z No Device	G Hand-Assisted X Diagnostic Z No Qualifier
FY2024	G Large Intestine, Left L Transverse Colon M Descending Colon N Sigmoid Colon	0 Open 3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	Z No Device	X Diagnostic Z No Qualifier
FY2024	G Large Intestine, Left L Transverse Colon M Descending Colon N Sigmoid Colon	4 Percutaneous Endoscopic	Z No Device	G Hand-Assisted X Diagnostic Z No Qualifier
No change	G Large Intestine, Left L Transverse Colon M Descending Colon N Sigmoid Colon	F Via Natural or Artificial Opening With Percutaneous Endoscopic Assistance	Z No Device	Z No Qualifier

No change	Q Anus	0 Open 3 Percutaneous 4 Percutaneous Endoscopic 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic X External	Z No Device	X Diagnostic Z No Qualifier
No change	R Anal Sphincter U Omentum V Mesentery W Peritoneum	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	Z No Device	X Diagnostic Z No Qualifier

ODT

No change	Section 0 Medical and Surgical			
	Body System D Gastrointestinal System			
	Operation T Resection: Cutting out or off, without replacement, all of a body part			
Heading	Body Part	Approach	Device	Qualifier
FY2024	1 Esophagus, Upper 2 Esophagus, Middle 3 Esophagus, Lower 4 Esophagogastric Junction 5 Esophagus 6 Stomach 7 Stomach, Pylorus 8 Small Intestine 9 Duodenum A Jejunum B Ileum C Ileocecal Valve E Large Intestine H Cecum K Ascending Colon P Rectum Q Anus	0 Open 4 Percutaneous Endoscopic 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	Z No Device	Z No Qualifier
FY2024	F Large Intestine, Right J Appendix	0 Open 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	Z No Device	Z No Qualifier
FY2024	F Large Intestine, Right J Appendix	4 Percutaneous Endoscopic	Z No Device	G Hand-Assisted Z No Qualifier
FY2024	G Large Intestine, Left L Transverse Colon M Descending Colon N Sigmoid Colon	0 Open 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic F Via Natural or Artificial Opening With Percutaneous Endoscopic Assistance	Z No Device	Z No Qualifier
FY2024	G Large Intestine, Left L Transverse Colon M Descending Colon N Sigmoid Colon	4 Percutaneous Endoscopic	Z No Device	G Hand-Assisted Z No Qualifier
No change	R Anal Sphincter U Omentum	0 Open 4 Percutaneous Endoscopic	Z No Device	Z No Qualifier

ODX

No change	Section 0 Medical and Surgical Body System D Gastrointestinal System Operation X Transfer: Moving, without taking out, all or a portion of a body part to another location to take over the function of all or a portion of a body part			
Heading	Body Part	Approach	Device	Qualifier
No change	6 Stomach	0 Open 4 Percutaneous Endoscopic	Z No Device	5 Esophagus
No change	8 Small Intestine	0 Open 4 Percutaneous Endoscopic	Z No Device	5 Esophagus B Bladder C Ureter, Right D Ureter, Left F Ureters, Bilateral
No change	E Large Intestine	0 Open 4 Percutaneous Endoscopic	Z No Device	5 Esophagus 7 Vagina B Bladder
FY2024	U Omentum	0 Open 4 Percutaneous Endoscopic	Z No Device	V Thoracic Region W Abdominal Region X Pelvic Region Y Inguinal Region

0FB

No change	Section 0 Medical and Surgical			
	Body System F Hepatobiliary System and Pancreas			
	Operation B Excision: Cutting out or off, without replacement, a portion of a body part			
Heading	Body Part	Approach	Device	Qualifier
FY2024	0 Liver 1 Liver, Right Lobe 2 Liver, Left Lobe	0 Open 3 Percutaneous	Z No Device	X Diagnostic Z No Qualifier
FY2024	0 Liver 1 Liver, Right Lobe 2 Liver, Left Lobe	4 Percutaneous Endoscopic	Z No Device	G Hand-Assisted X Diagnostic Z No Qualifier
FY2024	4 Gallbladder	0 Open 3 Percutaneous 4 Percutaneous Endoscopic 8 Via Natural or Artificial Opening Endoscopic	Z No Device	X Diagnostic Z No Qualifier
No change	5 Hepatic Duct, Right 6 Hepatic Duct, Left 7 Hepatic Duct, Common 8 Cystic Duct 9 Common Bile Duct C Ampulla of Vater D Pancreatic Duct F Pancreatic Duct, Accessory	0 Open 3 Percutaneous 4 Percutaneous Endoscopic 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	Z No Device	X Diagnostic Z No Qualifier
FY2024	G Pancreas	0 Open 3 Percutaneous 8 Via Natural or Artificial Opening Endoscopic	Z No Device	X Diagnostic Z No Qualifier
FY2024	G Pancreas	4 Percutaneous Endoscopic	Z No Device	G Hand-Assisted X Diagnostic Z No Qualifier

0FT

No change	Section 0 Medical and Surgical			
	Body System F Hepatobiliary System and Pancreas			
	Operation T Resection: Cutting out or off, without replacement, all of a body part			
Heading	Body Part	Approach	Device	Qualifier
FY2024	0 Liver 1 Liver, Right Lobe 2 Liver, Left Lobe 4 Gallbladder G Pancreas	0 Open	Z No Device	Z No Qualifier
FY2024	0 Liver 1 Liver, Right Lobe 2 Liver, Left Lobe 4 Gallbladder G Pancreas	4 Percutaneous Endoscopic	Z No Device	G Hand-Assisted Z No Qualifier
No change	5 Hepatic Duct, Right 6 Hepatic Duct, Left 7 Hepatic Duct, Common 8 Cystic Duct 9 Common Bile Duct C Ampulla of Vater D Pancreatic Duct F Pancreatic Duct, Accessory	0 Open 4 Percutaneous Endoscopic 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	Z No Device	Z No Qualifier

OTT

No change	<i>Section</i> 0 Medical and Surgical			
	<i>Body System</i> T Urinary System			
	<i>Operation</i> T Resection: Cutting out or off, without replacement, all of a body part			
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device</i>	<i>Qualifier</i>
FY2024	0 Kidney, Right	0 Open	Z No Device	Z No Qualifier
	1 Kidney, Left			
	2 Kidneys, Bilateral			
FY2024	0 Kidney, Right	4 Percutaneous Endoscopic	Z No Device	G Hand-Assisted Z No Qualifier
	1 Kidney, Left			
	2 Kidneys, Bilateral			
No change	3 Kidney Pelvis, Right	0 Open 4 Percutaneous Endoscopic 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	Z No Device	Z No Qualifier
	4 Kidney Pelvis, Left			
	6 Ureter, Right			
	7 Ureter, Left			
	B Bladder			
	C Bladder Neck			
	D Urethra			

0X6

No change	Section 0 Medical and Surgical			
	Body System X Anatomical Regions, Upper Extremities			
	Operation 6 Detachment: Cutting off all or a portion of the upper or lower extremities			
Heading	Body Part	Approach	Device	Qualifier
No change	0 Forequarter, Right 1 Forequarter, Left 2 Shoulder Region, Right 3 Shoulder Region, Left B Elbow Region, Right C Elbow Region, Left	0 Open	Z No Device	Z No Qualifier
No change	8 Upper Arm, Right 9 Upper Arm, Left D Lower Arm, Right F Lower Arm, Left	0 Open	Z No Device	1 High 2 Mid 3 Low
No change	J Hand, Right K Hand, Left	0 Open	Z No Device	0 Complete 4 Complete 1st Ray 5 Complete 2nd Ray 6 Complete 3rd Ray 7 Complete 4th Ray 8 Complete 5th Ray 9 Partial 1st Ray B Partial 2nd Ray C Partial 3rd Ray D Partial 4th Ray F Partial 5th Ray
FY2024	L Thumb, Right M Thumb, Left	0 Open	Z No Device	0 Complete 1 High 3 Low
FY2024	N Index Finger, Right P Index Finger, Left Q Middle Finger, Right R Middle Finger, Left S Ring Finger, Right T Ring Finger, Left V Little Finger, Right W Little Finger, Left	0 Open	Z No Device	0 Complete 1 High 2 Mid 3 Low

0Y6

No change	Section 0 Medical and Surgical			
	Body System Y Anatomical Regions, Lower Extremities			
	Operation 6 Detachment: Cutting off all or a portion of the upper or lower extremities			
Heading	Body Part	Approach	Device	Qualifier
No change	2 Hindquarter, Right 3 Hindquarter, Left 4 Hindquarter, Bilateral 7 Femoral Region, Right 8 Femoral Region, Left F Knee Region, Right G Knee Region, Left	0 Open	Z No Device	Z No Qualifier
No change	C Upper Leg, Right D Upper Leg, Left H Lower Leg, Right J Lower Leg, Left	0 Open	Z No Device	1 High 2 Mid 3 Low
No change	M Foot, Right N Foot, Left	0 Open	Z No Device	0 Complete 4 Complete 1st Ray 5 Complete 2nd Ray 6 Complete 3rd Ray 7 Complete 4th Ray 8 Complete 5th Ray 9 Partial 1st Ray B Partial 2nd Ray C Partial 3rd Ray D Partial 4th Ray F Partial 5th Ray
FY2024	P 1st Toe, Right Q 1st Toe, Left	0 Open	Z No Device	0 Complete 1 High 3 Low
FY2024	R 2nd Toe, Right S 2nd Toe, Left T 3rd Toe, Right U 3rd Toe, Left V 4th Toe, Right W 4th Toe, Left X 5th Toe, Right Y 5th Toe, Left	0 Open	Z No Device	0 Complete 1 High 2 Mid 3 Low

3E0

No change	Section 3 Administration Body System E Physiological Systems and Anatomical Regions Operation 0 Introduction: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products			
	Heading	Body System / Region	Approach	Substance
		Qualifier		
No change	0 Skin and Mucous Membranes	X External	0 Antineoplastic	5 Other Antineoplastic M Monoclonal Antibody
No change	0 Skin and Mucous Membranes	X External	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	0 Skin and Mucous Membranes	X External	3 Anti-inflammatory 4 Serum, Toxoid and Vaccine B Anesthetic Agent K Other Diagnostic Substance M Pigment N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	0 Skin and Mucous Membranes	X External	G Other Therapeutic Substance	C Other Substance
No change	1 Subcutaneous Tissue	0 Open	2 Anti-infective	A Anti-Infective Envelope
No change	1 Subcutaneous Tissue	3 Percutaneous	0 Antineoplastic	5 Other Antineoplastic M Monoclonal Antibody
No change	1 Subcutaneous Tissue	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective A Anti-Infective Envelope
No change	1 Subcutaneous Tissue	3 Percutaneous	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	1 Subcutaneous Tissue	3 Percutaneous	4 Serum, Toxoid and Vaccine	0 Influenza Vaccine Z No Qualifier
No change	1 Subcutaneous Tissue	3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	1 Subcutaneous Tissue	3 Percutaneous	V Hormone	G Insulin J Other Hormone
No change	2 Muscle	3 Percutaneous	0 Antineoplastic	5 Other Antineoplastic M Monoclonal Antibody
No change	2 Muscle	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	2 Muscle	3 Percutaneous	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier

No change	2 Muscle	3 Percutaneous	4 Serum, Toxoid and Vaccine	0 Influenza Vaccine Z No Qualifier
No change	2 Muscle	3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	3 Peripheral Vein	0 Open	0 Antineoplastic	2 High-dose Interleukin-2 3 Low-dose Interleukin-2 5 Other Antineoplastic M Monoclonal Antibody P Clofarabine
No change	3 Peripheral Vein	0 Open	1 Thrombolytic	6 Recombinant Human-activated Protein C 7 Other Thrombolytic
No change	3 Peripheral Vein	0 Open	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	3 Peripheral Vein	0 Open	3 Anti-inflammatory 4 Serum, Toxoid and Vaccine 6 Nutritional Substance 7 Electrolytic and Water Balance Substance F Intracirculatory Anesthetic H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives P Platelet Inhibitor R Antiarrhythmic T Destructive Agent X Vasopressor	Z No Qualifier
No change	3 Peripheral Vein	0 Open	G Other Therapeutic Substance	C Other Substance N Blood Brain Barrier Disruption
No change	3 Peripheral Vein	0 Open	U Pancreatic Islet Cells	0 Autologous 1 Nonautologous
No change	3 Peripheral Vein	0 Open	V Hormone	G Insulin H Human B-type Natriuretic Peptide J Other Hormone
No change	3 Peripheral Vein	0 Open	W Immunotherapeutic	K Immunostimulator L Immunosuppressive
No change	3 Peripheral Vein	3 Percutaneous	0 Antineoplastic	2 High-dose Interleukin-2 3 Low-dose Interleukin-2 5 Other Antineoplastic M Monoclonal Antibody P Clofarabine
No change	3 Peripheral Vein	3 Percutaneous	1 Thrombolytic	6 Recombinant Human-activated Protein C 7 Other Thrombolytic
No change	3 Peripheral Vein	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective

No change	3 Peripheral Vein	3 Percutaneous	3 Anti-inflammatory 4 Serum, Toxoid and Vaccine 6 Nutritional Substance 7 Electrolytic and Water Balance Substance F Intracirculatory Anesthetic H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives P Platelet Inhibitor R Antiarrhythmic T Destructive Agent X Vasopressor	Z No Qualifier
No change	3 Peripheral Vein	3 Percutaneous	G Other Therapeutic Substance	C Other Substance N Blood Brain Barrier Disruption Q Glucarpidase R Other Therapeutic Monoclonal Antibody
No change	3 Peripheral Vein	3 Percutaneous	U Pancreatic Islet Cells	0 Autologous 1 Nonautologous
No change	3 Peripheral Vein	3 Percutaneous	V Hormone	G Insulin H Human B-type Natriuretic Peptide J Other Hormone
No change	3 Peripheral Vein	3 Percutaneous	W Immunotherapeutic	K Immunostimulator L Immunosuppressive
No change	4 Central Vein	0 Open	0 Antineoplastic	2 High-dose Interleukin-2 3 Low-dose Interleukin-2 5 Other Antineoplastic M Monoclonal Antibody P Clofarabine
No change	4 Central Vein	0 Open	1 Thrombolytic	6 Recombinant Human-activated Protein C 7 Other Thrombolytic
No change	4 Central Vein	0 Open	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	4 Central Vein	0 Open	3 Anti-inflammatory 4 Serum, Toxoid and Vaccine 6 Nutritional Substance 7 Electrolytic and Water Balance Substance F Intracirculatory Anesthetic H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives P Platelet Inhibitor R Antiarrhythmic T Destructive Agent X Vasopressor	Z No Qualifier
No change	4 Central Vein	0 Open	G Other Therapeutic Substance	C Other Substance N Blood Brain Barrier Disruption
No change	4 Central Vein	0 Open	V Hormone	G Insulin H Human B-type Natriuretic Peptide J Other Hormone
No change	4 Central Vein	0 Open	W Immunotherapeutic	K Immunostimulator L Immunosuppressive

No change	4 Central Vein	3 Percutaneous	0 Antineoplastic	2 High-dose Interleukin-2 3 Low-dose Interleukin-2 5 Other Antineoplastic M Monoclonal Antibody P Clofarabine
No change	4 Central Vein	3 Percutaneous	1 Thrombolytic	6 Recombinant Human-activated Protein C 7 Other Thrombolytic
No change	4 Central Vein	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	4 Central Vein	3 Percutaneous	3 Anti-inflammatory 4 Serum, Toxoid and Vaccine 6 Nutritional Substance 7 Electrolytic and Water Balance Substance F Intracirculatory Anesthetic H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives P Platelet Inhibitor R Antiarrhythmic T Destructive Agent X Vasopressor	Z No Qualifier
No change	4 Central Vein	3 Percutaneous	G Other Therapeutic Substance	C Other Substance N Blood Brain Barrier Disruption Q Glucarpidase R Other Therapeutic Monoclonal Antibody
No change	4 Central Vein	3 Percutaneous	V Hormone	G Insulin H Human B-type Natriuretic Peptide J Other Hormone
No change	4 Central Vein	3 Percutaneous	W Immunotherapeutic	K Immunostimulator L Immunosuppressive
No change	5 Peripheral Artery 6 Central Artery	0 Open 3 Percutaneous	0 Antineoplastic	2 High-dose Interleukin-2 3 Low-dose Interleukin-2 5 Other Antineoplastic M Monoclonal Antibody P Clofarabine
No change	5 Peripheral Artery 6 Central Artery	0 Open 3 Percutaneous	1 Thrombolytic	6 Recombinant Human-activated Protein C 7 Other Thrombolytic
No change	5 Peripheral Artery 6 Central Artery	0 Open 3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	5 Peripheral Artery 6 Central Artery	0 Open 3 Percutaneous	3 Anti-inflammatory 4 Serum, Toxoid and Vaccine 6 Nutritional Substance 7 Electrolytic and Water Balance Substance F Intracirculatory Anesthetic H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives P Platelet Inhibitor R Antiarrhythmic T Destructive Agent X Vasopressor	Z No Qualifier
No change	5 Peripheral Artery 6 Central Artery	0 Open 3 Percutaneous	G Other Therapeutic Substance	C Other Substance N Blood Brain Barrier Disruption

No change	5 Peripheral Artery 6 Central Artery	0 Open 3 Percutaneous	V Hormone	G Insulin H Human B-type Natriuretic Peptide J Other Hormone
No change	5 Peripheral Artery 6 Central Artery	0 Open 3 Percutaneous	W Immunotherapeutic	K Immunostimulator L Immunosuppressive
No change	7 Coronary Artery 8 Heart	0 Open 3 Percutaneous	1 Thrombolytic	6 Recombinant Human-activated Protein C 7 Other Thrombolytic
No change	7 Coronary Artery 8 Heart	0 Open 3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	7 Coronary Artery 8 Heart	0 Open 3 Percutaneous	K Other Diagnostic Substance P Platelet Inhibitor	Z No Qualifier
No change	7 Coronary Artery 8 Heart	4 Percutaneous Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	9 Nose	3 Percutaneous 7 Via Natural or Artificial Opening X External	0 Antineoplastic	5 Other Antineoplastic M Monoclonal Antibody
No change	9 Nose	3 Percutaneous 7 Via Natural or Artificial Opening X External	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	9 Nose	3 Percutaneous 7 Via Natural or Artificial Opening X External	3 Anti-inflammatory 4 Serum, Toxoid and Vaccine B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	9 Nose	3 Percutaneous 7 Via Natural or Artificial Opening X External	G Other Therapeutic Substance	C Other Substance
No change	A Bone Marrow	3 Percutaneous	0 Antineoplastic	5 Other Antineoplastic M Monoclonal Antibody
No change	A Bone Marrow	3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	B Ear	3 Percutaneous 7 Via Natural or Artificial Opening X External	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	B Ear	3 Percutaneous 7 Via Natural or Artificial Opening X External	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	B Ear	3 Percutaneous 7 Via Natural or Artificial Opening X External	3 Anti-inflammatory B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	B Ear	3 Percutaneous 7 Via Natural or Artificial Opening X External	G Other Therapeutic Substance	C Other Substance

No change	C Eye	3 Percutaneous 7 Via Natural or Artificial Opening X External	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	C Eye	3 Percutaneous 7 Via Natural or Artificial Opening X External	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	C Eye	3 Percutaneous 7 Via Natural or Artificial Opening X External	3 Anti-inflammatory B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance M Pigment N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	C Eye	3 Percutaneous 7 Via Natural or Artificial Opening X External	G Other Therapeutic Substance	C Other Substance
No change	C Eye	3 Percutaneous 7 Via Natural or Artificial Opening X External	S Gas	F Other Gas
No change	D Mouth and Pharynx	3 Percutaneous 7 Via Natural or Artificial Opening X External	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	D Mouth and Pharynx	3 Percutaneous 7 Via Natural or Artificial Opening X External	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	D Mouth and Pharynx	3 Percutaneous 7 Via Natural or Artificial Opening X External	3 Anti-inflammatory 4 Serum, Toxoid and Vaccine 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives R Antiarrhythmic T Destructive Agent	Z No Qualifier
No change	D Mouth and Pharynx	3 Percutaneous 7 Via Natural or Artificial Opening X External	G Other Therapeutic Substance	C Other Substance
No change	E Products of Conception G Upper GI H Lower GI K Genitourinary Tract N Male Reproductive	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	E Products of Conception G Upper GI H Lower GI K Genitourinary Tract N Male Reproductive	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective

No change	E Products of Conception G Upper GI H Lower GI K Genitourinary Tract N Male Reproductive	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	E Products of Conception G Upper GI H Lower GI K Genitourinary Tract N Male Reproductive	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	E Products of Conception G Upper GI H Lower GI K Genitourinary Tract N Male Reproductive	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	S Gas	F Other Gas
No change	E Products of Conception G Upper GI H Lower GI K Genitourinary Tract N Male Reproductive	4 Percutaneous Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	F Respiratory Tract	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	F Respiratory Tract	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	F Respiratory Tract	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	F Respiratory Tract	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	F Respiratory Tract	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	S Gas	D Nitric Oxide F Other Gas
No change	F Respiratory Tract	4 Percutaneous Endoscopic	G Other Therapeutic Substance	C Other Substance

No change	J Biliary and Pancreatic Tract	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	J Biliary and Pancreatic Tract	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	J Biliary and Pancreatic Tract	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	J Biliary and Pancreatic Tract	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	J Biliary and Pancreatic Tract	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	S Gas	F Other Gas
No change	J Biliary and Pancreatic Tract	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	U Pancreatic Islet Cells	0 Autologous 1 Nonautologous
No change	J Biliary and Pancreatic Tract	4 Percutaneous Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	L Pleural Cavity	0 Open	5 Adhesion Barrier	Z No Qualifier
No change	L Pleural Cavity	3 Percutaneous	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
FY2024	L Pleural Cavity	3 Percutaneous	1 Thrombolytic	7 Other Thrombolytic
No change	L Pleural Cavity	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	L Pleural Cavity	3 Percutaneous	3 Anti-inflammatory 5 Adhesion Barrier 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	L Pleural Cavity	3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	L Pleural Cavity	3 Percutaneous	S Gas	F Other Gas

No change	L Pleural Cavity	4 Percutaneous Endoscopic	5 Adhesion Barrier	Z No Qualifier
No change	L Pleural Cavity	4 Percutaneous Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	L Pleural Cavity	7 Via Natural or Artificial Opening	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	L Pleural Cavity	7 Via Natural or Artificial Opening	S Gas	F Other Gas
No change	M Peritoneal Cavity	0 Open	5 Adhesion Barrier	Z No Qualifier
No change	M Peritoneal Cavity	3 Percutaneous	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody Y Hyperthermic
No change	M Peritoneal Cavity	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	M Peritoneal Cavity	3 Percutaneous	3 Anti-inflammatory 5 Adhesion Barrier 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	M Peritoneal Cavity	3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	M Peritoneal Cavity	3 Percutaneous	S Gas	F Other Gas
No change	M Peritoneal Cavity	4 Percutaneous Endoscopic	5 Adhesion Barrier	Z No Qualifier
No change	M Peritoneal Cavity	4 Percutaneous Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	M Peritoneal Cavity	7 Via Natural or Artificial Opening	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	M Peritoneal Cavity	7 Via Natural or Artificial Opening	S Gas	F Other Gas
No change	P Female Reproductive	0 Open	5 Adhesion Barrier	Z No Qualifier
No change	P Female Reproductive	3 Percutaneous	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	P Female Reproductive	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	P Female Reproductive	3 Percutaneous	3 Anti-inflammatory 5 Adhesion Barrier 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance L Sperm N Analgesics, Hypnotics, Sedatives T Destructive Agent V Hormone	Z No Qualifier

No change	P Female Reproductive	3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	P Female Reproductive	3 Percutaneous	Q Fertilized Ovum	0 Autologous 1 Nonautologous
No change	P Female Reproductive	3 Percutaneous	S Gas	F Other Gas
No change	P Female Reproductive	4 Percutaneous Endoscopic	5 Adhesion Barrier	Z No Qualifier
No change	P Female Reproductive	4 Percutaneous Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	P Female Reproductive	7 Via Natural or Artificial Opening	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	P Female Reproductive	7 Via Natural or Artificial Opening	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	P Female Reproductive	7 Via Natural or Artificial Opening	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance L Sperm N Analgesics, Hypnotics, Sedatives T Destructive Agent V Hormone	Z No Qualifier
No change	P Female Reproductive	7 Via Natural or Artificial Opening	G Other Therapeutic Substance	C Other Substance
No change	P Female Reproductive	7 Via Natural or Artificial Opening	Q Fertilized Ovum	0 Autologous 1 Nonautologous
No change	P Female Reproductive	7 Via Natural or Artificial Opening	S Gas	F Other Gas
No change	P Female Reproductive	8 Via Natural or Artificial Opening Endoscopic	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	P Female Reproductive	8 Via Natural or Artificial Opening Endoscopic	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	P Female Reproductive	8 Via Natural or Artificial Opening Endoscopic	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	P Female Reproductive	8 Via Natural or Artificial Opening Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	P Female Reproductive	8 Via Natural or Artificial Opening Endoscopic	S Gas	F Other Gas
No change	Q Cranial Cavity and Brain	0 Open 3 Percutaneous	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	Q Cranial Cavity and Brain	0 Open 3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective

No change	Q Cranial Cavity and Brain	0 Open 3 Percutaneous	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance A Stem Cells, Embryonic B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	Q Cranial Cavity and Brain	0 Open 3 Percutaneous	E Stem Cells, Somatic	0 Autologous 1 Nonautologous
No change	Q Cranial Cavity and Brain	0 Open 3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	Q Cranial Cavity and Brain	0 Open 3 Percutaneous	S Gas	F Other Gas
No change	Q Cranial Cavity and Brain	7 Via Natural or Artificial Opening	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	Q Cranial Cavity and Brain	7 Via Natural or Artificial Opening	S Gas	F Other Gas
No change	R Spinal Canal	0 Open	A Stem Cells, Embryonic	Z No Qualifier
No change	R Spinal Canal	0 Open	E Stem Cells, Somatic	0 Autologous 1 Nonautologous
No change	R Spinal Canal	3 Percutaneous	0 Antineoplastic	2 High-dose Interleukin-2 3 Low-dose Interleukin-2 4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	R Spinal Canal	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	R Spinal Canal	3 Percutaneous	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance A Stem Cells, Embryonic B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	R Spinal Canal	3 Percutaneous	E Stem Cells, Somatic	0 Autologous 1 Nonautologous
No change	R Spinal Canal	3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	R Spinal Canal	3 Percutaneous	S Gas	F Other Gas
No change	R Spinal Canal	7 Via Natural or Artificial Opening	S Gas	F Other Gas
No change	S Epidural Space	3 Percutaneous	0 Antineoplastic	2 High-dose Interleukin-2 3 Low-dose Interleukin-2 4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	S Epidural Space	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective

No change	S Epidural Space	3 Percutaneous	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	S Epidural Space	3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	S Epidural Space	3 Percutaneous	S Gas	F Other Gas
No change	S Epidural Space	7 Via Natural or Artificial Opening	S Gas	F Other Gas
No change	T Peripheral Nerves and Plexi X Cranial Nerves	3 Percutaneous	3 Anti-inflammatory B Anesthetic Agent T Destructive Agent	Z No Qualifier
No change	T Peripheral Nerves and Plexi X Cranial Nerves	3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	U Joints	0 Open	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	U Joints	0 Open	G Other Therapeutic Substance	B Recombinant Bone Morphogenetic Protein
No change	U Joints	3 Percutaneous	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	U Joints	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	U Joints	3 Percutaneous	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	U Joints	3 Percutaneous	G Other Therapeutic Substance	B Recombinant Bone Morphogenetic Protein C Other Substance
No change	U Joints	3 Percutaneous	S Gas	F Other Gas
No change	U Joints	4 Percutaneous Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	V Bones	0 Open	G Other Therapeutic Substance	B Recombinant Bone Morphogenetic Protein C Other Substance
No change	V Bones	3 Percutaneous	0 Antineoplastic	5 Other Antineoplastic M Monoclonal Antibody
No change	V Bones	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective

No change	V Bones	3 Percutaneous	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	V Bones	3 Percutaneous	G Other Therapeutic Substance	B Recombinant Bone Morphogenetic Protein C Other Substance
No change	V Bones	4 Percutaneous Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	W Lymphatics	3 Percutaneous	0 Antineoplastic	5 Other Antineoplastic M Monoclonal Antibody
No change	W Lymphatics	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	W Lymphatics	3 Percutaneous	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	W Lymphatics	3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	Y Pericardial Cavity	3 Percutaneous	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	Y Pericardial Cavity	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	Y Pericardial Cavity	3 Percutaneous	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	Y Pericardial Cavity	3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	Y Pericardial Cavity	3 Percutaneous	S Gas	F Other Gas
No change	Y Pericardial Cavity	4 Percutaneous Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	Y Pericardial Cavity	7 Via Natural or Artificial Opening	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	Y Pericardial Cavity	7 Via Natural or Artificial Opening	S Gas	F Other Gas

5A0

No change	Section 5 Extracorporeal or Systemic Assistance and Performance			
	Body System A Physiological Systems			
	Operation 0 Assistance: Taking over a portion of a physiological function by extracorporeal means			
Heading	Body System	Duration	Function	Qualifier
No change	2 Cardiac	1 Intermittent	1 Output	0 Balloon Pump 5 Pulsatile Compression 6 Other Pump D Impeller Pump
No change	2 Cardiac	2 Continuous	1 Output	0 Balloon Pump 5 Pulsatile Compression 6 Other Pump D Impeller Pump
No change	2 Cardiac	2 Continuous	2 Oxygenation	C Supersaturated
No change	5 Circulatory	1 Intermittent 2 Continuous	2 Oxygenation	1 Hyperbaric
No change	9 Respiratory	2 Continuous	0 Filtration	Z No Qualifier
Revise from	9 Respiratory	3 Less than 24 Consecutive Hours 4 24-96 Consecutive Hours 5 Greater than 96 Consecutive Hours	5 Ventilation	7 Continuous Positive Airway Pressure 8 Intermittent Positive Airway Pressure 9 Continuous Negative Airway Pressure A High Nasal Flow/Velocity B Intermittent Negative Airway Pressure Z No Qualifier
Revise to	9 Respiratory	3 Less than 24 Consecutive Hours 4 24-96 Consecutive Hours 5 Greater than 96 Consecutive Hours	5 Ventilation	7 Continuous Positive Airway Pressure 8 Intermittent Positive Airway Pressure 9 Continuous Negative Airway Pressure A High Flow/Velocity Cannula B Intermittent Negative Airway Pressure Z No Qualifier
No change	9 Respiratory	B Less than 8 Consecutive Hours C 8-24 Consecutive Hours D Greater than 24 Consecutive Hours	5 Ventilation	K Intubated Prone Positioning

GZB

FY2024	<i>Section</i> G Mental Health			
	<i>Body System</i> Z None			
	<i>Type</i> B Electroconvulsive Therapy: The application of controlled electrical voltages to treat a mental health disorder			
Heading	<i>Qualifier</i>	<i>Qualifier</i>	<i>Qualifier</i>	<i>Qualifier</i>
FY2024	0 Unilateral-Single Seizure 2 Bilateral-Single Seizure 4 Other Electroconvulsive Therapy	Z None	Z None	Z None

XW0

No change	Section	X	New Technology	
	Body System	W	Anatomical Regions	
	Operation	0	Introduction: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products	
Heading	Body Part	Approach	Device / Substance / Technology	Qualifier
No change	0 Skin	X External	2 Anacaulase-bcdb	7 New Technology Group 7
FY2024	1 Subcutaneous Tissue	3 Percutaneous	1 Daratumumab and Hyaluronidase-fihj	8 New Technology Group 8
FY2024	1 Subcutaneous Tissue	3 Percutaneous	2 Talquetamab Antineoplastic	9 New Technology Group 9
FY2024	1 Subcutaneous Tissue	3 Percutaneous	4 Teclistamab Antineoplastic	8 New Technology Group 8
No change	1 Subcutaneous Tissue	3 Percutaneous	9 Satralizumab-mwge	7 New Technology Group 7
No change	1 Subcutaneous Tissue	3 Percutaneous	F Other New Technology Therapeutic Substance	5 New Technology Group 5
No change	1 Subcutaneous Tissue	3 Percutaneous	G REGN-COV2 Monoclonal Antibody H Other New Technology Monoclonal Antibody K Lerolimab Monoclonal Antibody	6 New Technology Group 6
No change	1 Subcutaneous Tissue	3 Percutaneous	L Elranatamab Antineoplastic	9 New Technology Group 9
No change	1 Subcutaneous Tissue	3 Percutaneous	S COVID-19 Vaccine Dose 1	6 New Technology Group 6
No change	1 Subcutaneous Tissue	3 Percutaneous	S Epcoritamab Monoclonal Antibody	9 New Technology Group 9
No change	1 Subcutaneous Tissue	3 Percutaneous	T COVID-19 Vaccine Dose 2 U COVID-19 Vaccine	6 New Technology Group 6
No change	1 Subcutaneous Tissue	3 Percutaneous	V COVID-19 Vaccine Dose 3	7 New Technology Group 7
No change	1 Subcutaneous Tissue	3 Percutaneous	W Caplacizumab	5 New Technology Group 5
No change	1 Subcutaneous Tissue	3 Percutaneous	W COVID-19 Vaccine Booster	7 New Technology Group 7
No change	1 Subcutaneous Tissue	X External	2 Anacaulase-bcdb	7 New Technology Group 7
No change	2 Muscle	0 Open	D Engineered Allogeneic Thymus Tissue	8 New Technology Group 8
No change	2 Muscle	3 Percutaneous	S COVID-19 Vaccine Dose 1 T COVID-19 Vaccine Dose 2 U COVID-19 Vaccine	6 New Technology Group 6
No change	2 Muscle	3 Percutaneous	V COVID-19 Vaccine Dose 3 W COVID-19 Vaccine Booster X Tixagevimab and Cilgavimab Monoclonal Antibody Y Other New Technology Monoclonal Antibody	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	0 Brexanolone	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	0 Spesolimab Monoclonal Antibody	8 New Technology Group 8
No change	3 Peripheral Vein	3 Percutaneous	2 Nerinitide 3 Durvalumab Antineoplastic	6 New Technology Group 6

No change	3 Peripheral Vein	3 Percutaneous	5 Narsoplimab Monoclonal Antibody	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	5 Mosunetuzumab Antineoplastic	8 New Technology Group 8
No change	3 Peripheral Vein	3 Percutaneous	6 Lefamulin Anti-infective	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	6 Terlipressin	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	6 Afamitresgene Autoleucel Immunotherapy	8 New Technology Group 8
No change	3 Peripheral Vein	3 Percutaneous	7 Coagulation Factor Xa, Inactivated	2 New Technology Group 2
No change	3 Peripheral Vein	3 Percutaneous	7 Trilaciclib	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	7 Tabelecleucel Immunotherapy	8 New Technology Group 8
No change	3 Peripheral Vein	3 Percutaneous	8 Lurbinectedin	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	8 Treosulfan	8 New Technology Group 8
No change	3 Peripheral Vein	3 Percutaneous	9 Ceftolozane/Tazobactam Anti-infective	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	9 Inebilizumab-cdon	8 New Technology Group 8
No change	3 Peripheral Vein	3 Percutaneous	A Cefiderocol Anti-infective	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	A Ciltacabtagene Autoleucel	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	B Cytarabine and Daunorubicin Liposome Antineoplastic	3 New Technology Group 3
No change	3 Peripheral Vein	3 Percutaneous	B Omadacycline Anti-infective	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	B Amivantamab Monoclonal Antibody	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	C Eculizumab	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	D Atezolizumab Antineoplastic	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	E Remdesivir Anti-infective	5 New Technology Group 5
No change	3 Peripheral Vein	3 Percutaneous	E Etesevimab Monoclonal Antibody	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	3 New Technology Group 3
No change	3 Peripheral Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	5 New Technology Group 5
No change	3 Peripheral Vein	3 Percutaneous	F Bamlanivimab Monoclonal Antibody	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	G Sarilumab	5 New Technology Group 5
No change	3 Peripheral Vein	3 Percutaneous	G REGN-COV2 Monoclonal Antibody	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	H Tocilizumab	5 New Technology Group 5
No change	3 Peripheral Vein	3 Percutaneous	H Other New Technology Monoclonal Antibody	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	H Axicabtagene Ciloleucel Immunotherapy J Tisagenlecleucel Immunotherapy	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	K Fosfomycin Anti-infective	5 New Technology Group 5
No change	3 Peripheral Vein	3 Percutaneous	K Idecabtagene Vicleucel Immunotherapy	7 New Technology Group 7

No change	3 Peripheral Vein	3 Percutaneous	K Sulbactam-Durlobactam	9 New Technology Group 9
No change	3 Peripheral Vein	3 Percutaneous	L CD24Fc Immunomodulator	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	L Lifileucel Immunotherapy M Brexucabtagene Autoleucel Immunotherapy	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	N Meropenem-vaborbactam Anti-infective	5 New Technology Group 5
No change	3 Peripheral Vein	3 Percutaneous	N Lisocabtagene Maraleucel Immunotherapy	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	P Glofitamab Antineoplastic	9 New Technology Group 9
No change	3 Peripheral Vein	3 Percutaneous	Q Tagraxofusp-erzs Antineoplastic	5 New Technology Group 5
No change	3 Peripheral Vein	3 Percutaneous	Q Posoleucel R Rezafungin	9 New Technology Group 9
No change	3 Peripheral Vein	3 Percutaneous	S Iobenguane I-131 Antineoplastic U Imipenem-cilastatin-relebactam Anti-infective W Caplacizumab	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	0 Brexanolone	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	0 Spesolimab Monoclonal Antibody	8 New Technology Group 8
No change	4 Central Vein	3 Percutaneous	2 Nerinitide 3 Durvalumab Antineoplastic	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	5 Narsoplimab Monoclonal Antibody	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	5 Mosunetuzumab Antineoplastic	8 New Technology Group 8
No change	4 Central Vein	3 Percutaneous	6 Lefamulin Anti-infective	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	6 Terlipressin	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	6 Afamitresgene Autoleucel Immunotherapy	8 New Technology Group 8
No change	4 Central Vein	3 Percutaneous	7 Coagulation Factor Xa, Inactivated	2 New Technology Group 2
No change	4 Central Vein	3 Percutaneous	7 Trilaciclib	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	7 Tabelecleucel Immunotherapy	8 New Technology Group 8
No change	4 Central Vein	3 Percutaneous	8 Lurbinectedin	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	8 Treosulfan	8 New Technology Group 8
No change	4 Central Vein	3 Percutaneous	9 Ceftolozane/Tazobactam Anti-infective	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	9 Inebilizumab-cdon	8 New Technology Group 8
No change	4 Central Vein	3 Percutaneous	A Cefiderocol Anti-infective	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	A Cilta cabtagene Autoleucel	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	B Cytarabine and Daunorubicin Liposome Antineoplastic	3 New Technology Group 3
No change	4 Central Vein	3 Percutaneous	B Omadacycline Anti-infective	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	B Amivantamab Monoclonal Antibody	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	C Eculizumab	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	D Atezolizumab Antineoplastic	6 New Technology Group 6

No change	4 Central Vein	3 Percutaneous	E Remdesivir Anti-infective	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	E Etesevimab Monoclonal Antibody	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	3 New Technology Group 3
No change	4 Central Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	F Bamlanivimab Monoclonal Antibody	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	G Sarilumab	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	G REGN-COV2 Monoclonal Antibody	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	H Tocilizumab	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	H Other New Technology Monoclonal Antibody	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	H Axicabtagene Ciloleucel Immunotherapy J Tisagenlecleucel Immunotherapy	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	K Fosfomycin Anti-infective	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	K Idecabtagene Vicleucel Immunotherapy	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	K Sulbactam-Durlobactam	9 New Technology Group 9
No change	4 Central Vein	3 Percutaneous	L CD24Fc Immunomodulator	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	L Lifileucel Immunotherapy M Brexucabtagene Autoleucel Immunotherapy	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	N Meropenem-vaborbactam Anti-infective	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	N Lisocabtagene Maraleucel Immunotherapy	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	P Glofitamab Antineoplastic	9 New Technology Group 9
No change	4 Central Vein	3 Percutaneous	Q Tagraxofusp-erzs Antineoplastic	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	Q Posoleucel R Rezafungin	9 New Technology Group 9
No change	4 Central Vein	3 Percutaneous	S Iobenguane I-131 Antineoplastic U Imipenem-cilastatin-relebactam Anti-infective W Caplacizumab	5 New Technology Group 5
No change	5 Peripheral Artery	3 Percutaneous	T Melphalan Hydrochloride Antineoplastic	9 New Technology Group 9
No change	9 Nose	7 Via Natural or Artificial Opening	M Esketamine Hydrochloride	5 New Technology Group 5
No change	D Mouth and Pharynx	X External	3 Maribavir Anti-infective	8 New Technology Group 8
No change	D Mouth and Pharynx	X External	6 Lefamulin Anti-infective	6 New Technology Group 6
No change	D Mouth and Pharynx	X External	8 Uridine Triacetate	2 New Technology Group 2
No change	D Mouth and Pharynx	X External	F Other New Technology Therapeutic Substance J Apalutamide Antineoplastic	5 New Technology Group 5
No change	D Mouth and Pharynx	X External	J Quizartinib Antineoplastic	9 New Technology Group 9
No change	D Mouth and Pharynx	X External	K Sabizabulin	8 New Technology Group 8
No change	D Mouth and Pharynx	X External	L Erdafitinib Antineoplastic	5 New Technology Group 5

No change	D Mouth and Pharynx	X External	M Baricitinib	6 New Technology Group 6
No change	D Mouth and Pharynx	X External	N SER-109	9 New Technology Group 9
No change	D Mouth and Pharynx	X External	R Venetoclax Antineoplastic	5 New Technology Group 5
No change	D Mouth and Pharynx	X External	R Fostamatinib	7 New Technology Group 7
No change	D Mouth and Pharynx	X External	T Ruxolitinib V Gilteritinib Antineoplastic	5 New Technology Group 5
No change	G Upper GI	7 Via Natural or Artificial Opening	3 Maribavir Anti-infective K Sabizabulin	8 New Technology Group 8
No change	G Upper GI	7 Via Natural or Artificial Opening	M Baricitinib	6 New Technology Group 6
No change	G Upper GI	7 Via Natural or Artificial Opening	R Fostamatinib	7 New Technology Group 7
No change	G Upper GI	8 Via Natural or Artificial Opening Endoscopic	8 Mineral-based Topical Hemostatic Agent	6 New Technology Group 6
No change	H Lower GI	7 Via Natural or Artificial Opening	3 Maribavir Anti-infective K Sabizabulin	8 New Technology Group 8
No change	H Lower GI	7 Via Natural or Artificial Opening	M Baricitinib	6 New Technology Group 6
No change	H Lower GI	7 Via Natural or Artificial Opening	R Fostamatinib	7 New Technology Group 7
No change	H Lower GI	7 Via Natural or Artificial Opening	X Broad Consortium Microbiota-based Live Biotherapeutic Suspension	8 New Technology Group 8
No change	H Lower GI	8 Via Natural or Artificial Opening Endoscopic	8 Mineral-based Topical Hemostatic Agent	6 New Technology Group 6
No change	Q Cranial Cavity and Brain	3 Percutaneous	1 Eladocagene exuparvovec	6 New Technology Group 6
No change	V Bones	0 Open	P Antibiotic-eluting Bone Void Filler	7 New Technology Group 7

XX2

No change	<i>Section</i>	X	New Technology	
	<i>Body System</i>	X	Physiological Systems	
	<i>Operation</i>	2	Monitoring: Determining the level of a physiological or physical function repetitively over a period of time	
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
No change	0 Central Nervous	X External	8 Brain Electrical Activity, Computer-aided Detection and Notification	9 New Technology Group 9
No change	F Musculoskeletal	3 Percutaneous	W Muscle Compartment Pressure, Micro-Electro-Mechanical System	9 New Technology Group 9
FY2024	K Subcutaneous Tissue	X External	P Interstitial Fluid Volume, Sub-Epidermal Moisture using Electrical Biocapacitance	9 New Technology Group 9